Kolltan Pharmaceuticals
New Haven · Founded 2007
About Kolltan Pharmaceuticals
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation ’ at atomic resolution ’ for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Company Facts
- Founded: 2007
- Legal name: Kolltan Pharmaceuticals, Inc.
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $146.0M
- Funding stage: M&A
- Last round: Series D (Mar 2014)
- Website: kolltan.com
- Phone: 203-773-3000
Social Profiles
Canonical: https://fsome.com/organization/kolltan-pharmaceuticals-8442935 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.